Why universities work with IN-PART

IN-PART is our gateway to the universe of industry collaborations, a valuable partner whose contribution goes beyond marketing and facilitating discussions with the right people in industry. IN-PART brings results and has become our strategic (plus not to mention fun) friend on the road of transferring new technologies to the development stage, which is an important step towards the improvement of our overall health and well-being.

IN-PART is the best platform we’ve ever worked with! We’ve been subscribed since the start of 2018, and have received a range of useful introductions and feedback for our technologies from relevant companies in Europe and beyond.

In the first month of using IN-PART, we have received interest from senior R&D contacts at two world leading Pharmaceutical companies regarding one of our technologies posted. Discussions have taken place with one of the companies which will be followed by interaction with a relevant technical contact under CDA… We’ve been impressed by the seniority and relevance of introductions we’ve received via IN-PART and the outlook for tangible benefit from these contacts looks extremely positive.

The Technology Development and Commercialization Office at the University Health Network, which is the largest research hospital in Canada, has particularly enjoyed working with IN-PART and its various services and platforms. In the short 6 months, we’ve not only seen traction on a number of key technologies from industry, but also have valued the interaction with IN-PART’s team. Sarah and the whole IN-PART team have been professional, provided timely and impeccable responses to various challenges, connected us to several potential licensees and made us feel like the IN-PART team was just in the next office.

Cambridge Enterprise (the commercialisation office of the University of Cambridge) was introduced through IN-PART to a company with a specific problem that could potentially be addressed by one of our posted technologies, being commercialised through a spin-out. CE would not have identified the opportunity to collaborate with the company without the introduction from IN-PART – the technology has many possible uses and it can be difficult for a tech transfer office to find good contacts in these cases

IN-PART is a great service with much to offer. Not only have we received numerous inquiries from high level contacts allowing us to grow our own database, we have learned a lot about industry interest from Impact Reports and discussions with new contacts. In addition to gaining potential licensees, our subscription has even led to a sponsored research agreement proving the invaluable service of IN-PART.

This was a completely new interaction and one that would not have occurred without our project summary being present on IN-PART. It began by an overarching conversation with the Business Development and partnering team, which then moved initially on to non-confidential discussions with the academic. Axol worked with their marketing team to scout interest in this product and this was followed up by a meeting in person under CDA to discuss board project proposals.

IN-PART helped us to make a connection with a large pharmaceutical company, in order to discuss a potential collaboration around a unique drug screening platform. (...) From [our] discussions came several action items and we are very excited about the potential of forming a long term, impactful relationship with the company. IN-PART was critical in helping to connect us with the key people to discuss potential collaborations.

Working with IN-PART has been wholly positive, with access to a broad range of high-level decision makers searching for new partnering opportunities. Likewise, having a reliable contact within IN-PART has made our interaction with industry even easier.